Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 18,629 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Clear all
Completed Phase 1 Interventional Results available

Cockroach Nasal Allergen Challenge Pilot

NCT02710136
View directory record Official record
Conditions
Asthma, Cockroach Hypersensitivity
Interventions
Glycerinated German Cockroach Allergenic Extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional

Growing Healthy Hearts: An Online Gardening Program for Adults With Risk Factors for Cardiovascular Disease

NCT05720611
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Digitally delivered gardening and healthy eating course
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 23, 2026, 2:41 AM EDT
Active, not recruiting Phase 2 Interventional

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

NCT05482971
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Ropeginterferon alfa-2b-njft (P1101)
Drug
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Duarte, California • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

NCT01730937
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
Sorafenib, stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
41
States / cities
Berkeley, California • Los Angeles, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

NCT05297045
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RGT001-075, Placebo
Drug · Other
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

ARQ 197 in Subjects With Metastatic Solid Tumors

NCT00302172
View directory record Official record
Conditions
Cancer, Tumor
Interventions
ARQ 197
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Santa Monica, California • Cleveland, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2009 · Synced Oct 23, 2026, 2:41 AM EDT
Active, not recruiting Phase 4 Interventional

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095
View directory record Official record
Conditions
Eosinophilic Oesophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 2 Interventional

Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00062075
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia
Interventions
romidepsin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00624936
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Vidaza, Velcade
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 23, 2026, 2:41 AM EDT
Recruiting No phase listed Observational

Emgality for Migraine in Breastmilk

NCT06085144
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Active, not recruiting Not applicable Interventional

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

NCT05925634
View directory record Official record
Conditions
Myocardial Infarction, Coronary Artery Bypass, Percutaneous Coronary Intervention, Heart Failure, Cardiac Valve Surgery
Interventions
RPE (usual care), GXT+THHR (intervention)
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
60 Years to 99 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Springfield, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed No phase listed Observational

SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease

NCT00002563
View directory record Official record
Conditions
Lymphoma, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2005
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Iowa City, Iowa • Worcester, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 23, 2026, 2:41 AM EDT
Recruiting Phase 2 Interventional

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LY4268989, Mirikizumab, LY4268989 Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 1 Interventional

L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003430
View directory record Official record
Conditions
Head and Neck Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
L-778,123
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease

NCT00600665
View directory record Official record
Conditions
Anemia, Sickle Cell, Hemoglobin SC Disease
Interventions
PAINReportIt (Phase 1 + 2), PAINUCope (Phase 1), PAINConsultN (Phase 2), PAINUCope (Phase 2)
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 2 Interventional

Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity

NCT05017571
View directory record Official record
Conditions
Obesity, Insulin Resistance, Inflammation
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

GLASSIA Infusion Rate Study

NCT01651351
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency, Healthy Volunteers
Interventions
Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional

VR for Pain Management During Adult Burn Dressing Change

NCT04545229
View directory record Official record
Conditions
Pain, Burns
Interventions
VR-based Pain Alleviation Tool (VR-PAT)
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Not applicable Interventional

Measuring and Improving Coproduction Using coopeRATE

NCT04060329
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Disease
Interventions
coopeRATE Prompt
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
San Diego, California • Denver, Colorado • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01469637
View directory record Official record
Conditions
Healthy
Interventions
sulfamethoxazole + MMX placebo, Sulfamethoxazole + MMX Mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 23, 2026, 2:41 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
51
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Blood Donor CVD 9000

NCT03724357
View directory record Official record
Conditions
Cholera Vaccination
Interventions
Vaxchora
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Compare Active Tymbion Iontophoresis to Sham Tymbion Iontophoresis for Anesthesia of the Tympanic Membrane

NCT03119181
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Tymbion Lidocaine/epinephrine solution, Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution
Drug · Combination Product
Lead sponsor
Tusker Medical
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
San Jose, California • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

NCT03683719
View directory record Official record
Conditions
Chronic Hand Eczema
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Tucson, Arizona • Hialeah, Florida • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 23, 2026, 2:41 AM EDT